MX2024009966A - Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica - Google Patents

Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica

Info

Publication number
MX2024009966A
MX2024009966A MX2024009966A MX2024009966A MX2024009966A MX 2024009966 A MX2024009966 A MX 2024009966A MX 2024009966 A MX2024009966 A MX 2024009966A MX 2024009966 A MX2024009966 A MX 2024009966A MX 2024009966 A MX2024009966 A MX 2024009966A
Authority
MX
Mexico
Prior art keywords
hydroxytryptophan
tryptophan
medicament
pharmaceutical composition
degradation inhibitor
Prior art date
Application number
MX2024009966A
Other languages
English (en)
Spanish (es)
Inventor
Joachim Kamprad
Original Assignee
Joachim Kamprad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joachim Kamprad filed Critical Joachim Kamprad
Publication of MX2024009966A publication Critical patent/MX2024009966A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
MX2024009966A 2022-02-16 2024-08-14 Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica MX2024009966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102022103658.8A DE102022103658A1 (de) 2022-02-16 2022-02-16 Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
PCT/EP2023/053129 WO2023156275A1 (en) 2022-02-16 2023-02-08 Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor

Publications (1)

Publication Number Publication Date
MX2024009966A true MX2024009966A (es) 2024-11-08

Family

ID=85221827

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009966A MX2024009966A (es) 2022-02-16 2024-08-14 Composicion farmaceutica y medicamento que comprenden l-triptofano, l-5-hidroxitriptofano y un inhibidor de la degradacion periferica

Country Status (10)

Country Link
US (1) US20250161270A1 (cg-RX-API-DMAC10.html)
EP (1) EP4479027A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505294A (cg-RX-API-DMAC10.html)
KR (1) KR20240152875A (cg-RX-API-DMAC10.html)
CN (1) CN118871096A (cg-RX-API-DMAC10.html)
AU (1) AU2023222362A1 (cg-RX-API-DMAC10.html)
CA (1) CA3243635A1 (cg-RX-API-DMAC10.html)
DE (1) DE102022103658A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024009966A (cg-RX-API-DMAC10.html)
WO (1) WO2023156275A1 (cg-RX-API-DMAC10.html)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
CH652025A5 (de) 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DE3642668A1 (de) 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
EP1751312A4 (en) * 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
DE102004039196B4 (de) 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US20060257469A1 (en) * 2005-04-05 2006-11-16 Bulka Yochanan R Enhanced indoleamine and catecholamine bio-availability via catechin inhibition of L-Dopa decarboxylase
ES2948788T3 (es) * 2018-01-29 2023-09-19 Univ Duke Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano

Also Published As

Publication number Publication date
JP2025505294A (ja) 2025-02-21
WO2023156275A1 (en) 2023-08-24
CA3243635A1 (en) 2023-08-24
DE102022103658A1 (de) 2023-08-17
EP4479027A1 (en) 2024-12-25
AU2023222362A1 (en) 2024-09-12
CN118871096A (zh) 2024-10-29
KR20240152875A (ko) 2024-10-22
US20250161270A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CO2024003949A2 (es) Inhibidores de parp1 de azetidina y pirrolidina y usos de estos
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
ECSP22023220A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
UY40021A (es) Inhibidores lisina acetiltransferasa 6a (kat6a) y usos de los mismos
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
DOP2024000209A (es) Compuestos de heteroarilo para el tratamiento del dolor
UY40235A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2022008875A (es) Inhibidores terapeuticos de tirosina quinasa para esclerosis multiple recidivante (emr).
CL2021000793A1 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
MX2025014135A (es) Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos
ECSP099706A (es) Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor
MX2022013081A (es) Compuestos para el tratamiento de sars.
CR20180494A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
CL2022002564A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
CL2020000271A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr y un inhibidor de quinasa dependiente de ciclina.
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
CL2017001913A1 (es) Composición tópica curativa
BR112024001927A2 (pt) Formas de dosagem gastrorretentivas de 5-hidroxitriptofano
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
CL2021000282A1 (es) Inhibidores de ckd8/19